title: Nateglinide with glibenclamide examination using the respiratory quotient (RQ).
abstract: OBJECTIVE
  The respiratory quotient (RQ) is useful for evaluating glucose and lipid metabolism in vivo. We previously reported that the RQ value, even after fasting, was high in diabetics being treated with sulphonylurea (SU), which might explain the accumulation of fat, leading to weight gain in such individuals. In the present study, we measured the RQ in type II diabetic patients who were being treated with a rapid-onset/short-duration insulinotropic agent, nateglinide, and compared it with those being treated with SU.
  
  
  METHODS
  A glucose tolerance test was performed in 20 patients with type II diabetes mellitus treated with nateglinide and in 14 patients treated with SU, and the RQ was simultaneously measured.
  
  
  RESULTS
  The RQ values in the patients treated with nateglinide, were similar to those in healthy adults, but was lower than in those treated with SU. No weight gain was observed in patients treated with nateglinide.
  
  
  CONCLUSIONS
  A significant weight gain was reported in subjects treated with SU, accompanied by an increase in RQ. However, weight gain was less frequent in diabetics treated with nateglinide.
authors.affiliation: Department of Digestive and Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School.
authors.forename: Shinji
authors.initials: S
authors.lastname: Harada
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nomura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nakaya
authors.forename: Susumu
authors.initials: S
authors.lastname: Ito
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight / Q000502:physiology; D003510:Cyclohexanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology; D050356:Lipid Metabolism / Q000187:drug effects / Q000502:physiology; D008055:Lipids / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015430:Weight Gain
chemical_list: D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D008055:Lipids; D000077715:Nateglinide; D010649:Phenylalanine; D005905:Glyburide